Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07173582

"Matrix Metalloproteinases 7 and 9 in Rheumatoid Arthritis Patients With Interstitial Lung Disease"

Sponsor: Assiut University

View on ClinicalTrials.gov

Summary

This case control study will be done at Rheumatology Department, Assiut University Hospital. It will include RA patients fulfilling the American College of Rheumatology and European League against Rheumatism (ACR / EULAR) 2010 classification criteria. Aim of the study * To assess the matrix metalloproteinase 7 and 9 (MMP7,9) as a screening tool for interstitial lung disease in rheumatoid arthritis patients and to assess for correlation with RA-disease activity. * To investigate whether certain MMPs could be potential biomarkers reflecting the lung fibrotic process in RA patients. * To assess the capillaroscopy changes in RA and RA-ILD. * To detect correlation between MMPs and capillaroscopic changes in RA patients. This case control study will be done at Rheumatology Department, Assiut University Hospital. It will include RA patients fulfilling the American College of Rheumatology and European League against Rheumatism (ACR / EULAR) 2010 classification criteria. The patients will be divided into 3 groups: Group (1): RA patients with ILD. Group (2): RA patients without ILD Group (3): Healthy controls All patients will be subjected to: A- Complete medical history: Detailed medical history will be taken including demographic data (age, sex, disease duration, morning stiffness, joint involvement, smoking, habits of medical importance), articular and extra articular manifestations. Detailed respiratory manifestations as (dyspnea, cough, chest wheeze, others) B- Clinical examination: * General and local rheumatological examination. * Local chest examination (inspection, palpation, percussion, auscultation). * Assessment of RA disease activity using DAS 28 ESR. Score interpretation \<2.6 suggests disease remission. 2.6-3.2 suggests low disease activity 3.2-5.1 suggests moderate disease activity \>5.1 suggest high disease activity C- Laboratory investigations: Peripheral venous blood samples for CBC, C-reactive protein, erythrocyte sedimentation rate, antibody status. D- Radiology and PFT: PFTs and HRCT chest patterns will be done for patients. E- MMP measurement: Serum samples will be collected at the time of registry enrollment, MMP 7 and 9 concentrations will be measured using enzyme-linked immunosorbent assas. This ELISA kit uses the Sandwich-ELISA principle.

Official title: "Matrix Metalloproteinases 7 and 9 in Rheumatoid Arthritis Patients With Interstitial Lung Disease and Its Relation to Disease Activity"

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

81

Start Date

2025-10

Completion Date

2027-04

Last Updated

2025-09-15

Healthy Volunteers

Yes

Interventions

DIAGNOSTIC_TEST

Serum samples will be collected at the time of registry enrollment, MMP 7 and 9 concentrations will be measured using enzyme-linked immunosorbent assays.

All patients will be subjected to: A- Complete medical history: including demographic data (age, sex, disease duration, morning stiffness, joint involvement, smoking, habits of medical importance), articular and extra articular manifestations. Detailed respiratory manifestations. B- Clinical examination: * General and local rheumatologic examination. * Local chest examination (inspection, palpation, percussion, auscultation). * Assessment of RA disease activity using DAS 28 ESR. C- Laboratory investigations: CBC, C-reactive protein, erythrocyte sedimentation rate, antibody status. D- Radiology and PFT: PFTs and HRCT chest patterns will be done for patients. E- MMP measurement: MMP 7 and 9 concentrations will be measured using enzyme-linked immunosorbent assays. F. The capillaroscopy procedure

Locations (1)

Assuit University

Asyut, Egypt